Effect of Tiotropium Bromide Adjuvant Therapy on Clinical Outcome,Lung Function and Hemorheological Indexes in Patients with COPD
郑水猛 1杨志杰 2张凯莉1
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 福建省惠安县医院 呼吸内科,福建 惠安 362100
2. 福建省惠安县医院 综合内科,福建 惠安 362100
折叠
摘要
目的 探讨噻托溴铵辅助治疗对慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)患者临床疗效、肺功能及血液流变学指标的影响.方法 选取2022年8月—2024年1月惠安县医院收治的203 例COPD患者为研究对象,按照治疗方案分为对照组(茶碱缓释片,n=101)和辅助组(茶碱缓释片+噻托溴铵,n=102).比较并分析两组临床疗效、肺功能[用力肺活量(forced vital capacity,FVC)、第1秒用力呼气容积(forced expiratory volume in the first second,FEV1)及FEV1/FVC]、血液流变学指标[纤维蛋白原(fibrinogen,FIB)、血浆黏度(plasma viscosity,PV)、红细胞聚集指数(red blood cell aggregation index,RAI)]和不良反应发生率.结果 辅助组治疗总有效率94.12%,对照组治疗总有效率77.23%,两组临床疗效对比,辅助组比对照组高(P＜0.05);与治疗前相比较,两组治疗后FEV1、FVC、FEV1/FVC值均上升,辅助组比对照组高(P＜0.05);治疗后辅助组和对照组FIB、PV、RAI均下降,且辅助组比对照组低(P＜0.05);对照组不良反应总发生率13.86%,辅助组不良反应总发生率17.65%,两组比较差异无统计学意义(P＞0.05).结论 COPD患者应用噻托溴铵辅助治疗可有效改善肺功能、血液流变学指标,且临床疗效显著,未发生严重不良反应,安全可靠.
Abstract
Objective To investigate the effects of Tiotropium Bromide adjuvant therapy on clinical efficacy,lung function and hemorheological indexes in patients with chronic obstructive pulmonary disease(COPD).Methods 203 COPD patients admitted to Huian People's Hospital from August 2022 to January 2024 were selected for the study,and were divided into the control group(Theophylline extended-release tablets,n=101)and the auxiliary group(Theophylline extended-release tablets+Tiotropium Bromide,n=102)according to the treatment protocol.Clinical efficacy,pulmonary function[forced vital capacity(FVC),forced expiratory volume in the first second(FEV1)and FEV1/FVC],hemorheological indexes[fibrinogen(FIB),plasma viscosity(PV),red blood cell aggregation index(RAI)]and the occurrence of adverse reactions were compared and analyzed between the two groups.Results The total effective rate of the auxiliary group was 94.12%,and the total effective rate of the control group was 77.23%.The clinical efficacy of the two groups was significantly higher in the auxiliary group than in the control group(P＜0.05).Compared with the pre-treatment period,the FEV1,FVC,and FEV1/FVC values of the two groups after treatment were significantly higher,in which the auxiliary group was higher than the control group(P＜0.05).FIB,PV and RAI decreased in the auxiliary group and control group after treatment,and the auxiliary group was significantly lower than the control group(P＜0.05).The total incidence of adverse reactions was 13.86%in the control group and 17.65%in the auxiliary group,and there was no significant difference between the two groups(P＞0.05).Conclusion Tiotropium Bromide adjuvant therapy can effectively improve lung function and hemorheological indexes of COPD patients,and the clinical efficacy is remarkable,without serious adverse reactions,safe and reliable.
关键词
噻托溴铵/COPD/临床疗效/肺功能/血液流变学指标
Key words
Tiotropium Bromide/COPD/clinical efficacy/pulmonary function/hemorheological index
维普
万方数据